Key Highlights

  • INVO Fertility (NASDAQ:IVF) traded at USD 0.5359, down 5.98%, in pre-market trading on Tuesday, October 27, 2026, with no company-specific announcement dated on or just before the session accompanying the move.
  • For the quarter ended June 30, 2026, revenue rose 17% to USD 2,175,485, and net income was USD 888,740, which included a USD 2,452,032 gain on remeasurement tied to the Birmingham acquisition.
  • Adjusted EBITDA was a loss of USD 1,032,660, cash was USD 3.7 million at June 30, 2026, and the company operates four fertility clinics in the United States after the Indiana acquisition.
  • The pre-market quote is a thinly traded snapshot, and the company disclosed Nasdaq late-filing notices in 2026 and completed a 1-for-5 reverse split effective Friday, March 27, 2026.

The Pre-Market Move and Its Catalyst

INVO Fertility (NASDAQ:IVF), an operator of fertility clinics and a provider of an intravaginal culture device for in vitro fertilisation, traded at USD 0.5359, down 5.98%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The decline therefore appears consistent with the thin liquidity of pre-market sessions and with the volatility of a micro-cap stock priced below USD 1.00. The most recent formal disclosure was the company's release of Monday, August 17, 2026, which covered the second quarter of 2026. The snapshot can change before the open at 9:30 a.m. ET.

How the Latest Results Frame the Move

The company's release of Monday, August 17, 2026 reported revenue of USD 2,175,485 for the quarter ended June 30, 2026, up 17% from USD 1,863,654, with clinic revenue of USD 2,167,785, up 18%. Net income was USD 888,740 against a net loss of USD 3,618,969 a year earlier, but the result included a USD 2,452,032 non-cash gain on remeasurement tied to the Birmingham, Alabama clinic. Basic earnings per share were USD 0.42. Adjusted EBITDA, a non-GAAP measure of operating earnings, was a loss of USD 1,032,660 against a loss of USD 587,229. Clinic-level adjusted EBITDA before corporate expenses was USD 333,026. Cash was USD 3.7 million. The gain therefore explains the reported profit, while underlying operations remain loss-making.

Risks and What to Watch

The bull reading rests on revenue growth, the full-quarter contribution of Family Beginnings in Indiana, which was acquired in February 2026, full ownership of the Birmingham clinic from June 2026 and positive clinic-level adjusted EBITDA. The bear reading rests on the wider adjusted EBITDA loss, cash of USD 3.7 million and the non-recurring nature of the remeasurement gain. Named risks include dilution to fund acquisitions, listing compliance given the Nasdaq late-filing notices disclosed for the Form 10-K and a Form 10-Q, and integration of acquired clinics. The company gave no quantitative guidance. Investors should watch the Wednesday, October 28, 2026 Fed decision, any financing announcement, further clinic acquisitions and the third-quarter 2026 results release.

Where Things Stand

The answer is that INVO Fertility (NASDAQ:IVF) appears to have dropped 5.98% pre-market because of thin liquidity in a sub-USD 1.00 stock, since no company-specific announcement accompanied the move. The key number is the quarterly adjusted EBITDA loss of USD 1,032,660 against reported net income of USD 888,740. The next catalysts are the Fed decision on Wednesday, October 28, 2026, any financing or acquisition announcement and the third-quarter 2026 results release. Pre-market prices are snapshots and can change, and this is not investment advice.